🚀 VC round data is live in beta, check it out!
Korro Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Korro Bio and similar public comparables like Bioventix, Anixa Biosciences, SDI Group, 4basebio and more.
Korro Bio Overview
About Korro Bio
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Founded
2014
HQ
Employees
104
Website
Financials (LTM)
EV
$56M
Korro Bio Financials
Korro Bio reported last 12-month revenue of $5M.
In the same LTM period, Korro Bio generated $5M in gross profit and had net loss of ($106M).
Revenue (LTM)
Korro Bio P&L
In the most recent fiscal year, Korro Bio reported revenue of $6M and EBITDA of ($83M).
Korro Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $5M | XXX | $6M | XXX | XXX | XXX |
| Gross Profit | $5M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($83M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1298%) | XXX | XXX | XXX |
| EBIT Margin | (2074%) | XXX | (1365%) | XXX | XXX | XXX |
| Net Profit | ($106M) | XXX | ($117M) | XXX | XXX | XXX |
| Net Margin | (1998%) | XXX | (1832%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Korro Bio Stock Performance
Korro Bio has current market cap of $104M, and enterprise value of $56M.
Market Cap Evolution
Korro Bio's stock price is $11.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $56M | $104M | 0.0% | XXX | XXX | XXX | $-12.45 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKorro Bio Valuation Multiples
Korro Bio trades at 10.5x EV/Revenue multiple, and (0.7x) EV/EBITDA.
EV / Revenue (LTM)
Korro Bio Financial Valuation Multiples
As of April 8, 2026, Korro Bio has market cap of $104M and EV of $56M.
Equity research analysts estimate Korro Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Korro Bio has a P/E ratio of (1.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $104M | XXX | $104M | XXX | XXX | XXX |
| EV (current) | $56M | XXX | $56M | XXX | XXX | XXX |
| EV/Revenue | 10.5x | XXX | 8.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.7x) | XXX | XXX | XXX |
| EV/EBIT | (0.5x) | XXX | (0.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 10.5x | XXX | — | XXX | XXX | XXX |
| P/E | (1.0x) | XXX | (0.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Korro Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Korro Bio Margins & Growth Rates
Korro Bio's revenue in the last 12 month declined by (61%).
Korro Bio's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.9M for the same period.
Korro Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (61%) | XXX | (64%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1298%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (6%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 505% | XXX | 440% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1161% | XXX | 1026% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1465% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Korro Bio Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics and Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bioventix | XXX | XXX | XXX | XXX | XXX | XXX |
| Anixa Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| SDI Group | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Pacific Edge | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Korro Bio M&A Activity
Korro Bio acquired XXX companies to date.
Last acquisition by Korro Bio was on XXXXXXXX, XXXXX. Korro Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Korro Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKorro Bio Investment Activity
Korro Bio invested in XXX companies to date.
Korro Bio made its latest investment on XXXXXXXX, XXXXX. Korro Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Korro Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Korro Bio
| When was Korro Bio founded? | Korro Bio was founded in 2014. |
| Where is Korro Bio headquartered? | Korro Bio is headquartered in United States. |
| How many employees does Korro Bio have? | As of today, Korro Bio has over 104 employees. |
| Who is the CEO of Korro Bio? | Korro Bio's CEO is Ram Aiyar. |
| Is Korro Bio publicly listed? | Yes, Korro Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Korro Bio? | Korro Bio trades under KRRO ticker. |
| When did Korro Bio go public? | Korro Bio went public in 2023. |
| Who are competitors of Korro Bio? | Korro Bio main competitors are Bioventix, Anixa Biosciences, SDI Group, 4basebio. |
| What is the current market cap of Korro Bio? | Korro Bio's current market cap is $104M. |
| What is the current revenue of Korro Bio? | Korro Bio's last 12 months revenue is $5M. |
| What is the current revenue growth of Korro Bio? | Korro Bio revenue growth (NTM/LTM) is (61%). |
| What is the current EV/Revenue multiple of Korro Bio? | Current revenue multiple of Korro Bio is 10.5x. |
| Is Korro Bio profitable? | No, Korro Bio is not profitable. |
| What is the current net income of Korro Bio? | Korro Bio's last 12 months net income is ($106M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.